Abstract: An immunogenic composition includes as an effective ingredient an antigen-adjuvant microparticle complex containing an antigen encapsulated in an adjuvant microparticle composed of an amphiphilic polymer(s) whose hydrophobic segment is a poly(hydroxy acid), or a particle composed of the antigen-adjuvant microparticle complex associated together, can induce a high immune response against the antigen even with a small amount of the antigen and a small number of doses, so that the immunogenic composition is useful as a vaccine effective for therapy and prophylaxis of infectious diseases, cancer and the like.

Abstract: A method for nasal administration of a pharmaceutical composition comprising a hydrophilic bioactive substance and any one of (a) to (c): (a) a peptide having the amino acid sequence shown in SEQ ID NO:1; (b) a peptide having the same amino acid sequence as shown in SEQ ID NO:1 except that one or several amino acids are deleted, substituted and/or added, the peptide having nasal mucosal permeability; (c) a peptide having an amino acid sequence represented by the reverse sequence of (a) or (b), the peptide having nasal mucosal permeability, with the proviso that a C-terminal amidated peptide is excluded. A hydrophilic bioactive substance having a low transmucosal absorption capability which has conventionally been able to be administered by only injection can be nasally administered. Such a pharmaceutical composition is useful for improvement of the pain and the inconvenience of patients caused by administration by injection.

Abstract: A cell-penetrating peptide of (A) to (D) below gives cell membrane permeability and transmucosal absorbability to a physiologically active substance: (A) a peptide having the amino acid sequence of SEQ ID NO:1; (B) a peptide represented by SEQ ID NO:1 except that one or several basic amino acids are changed; (C) a peptide represented by SEQ ID NO:1 except that 1 to 5 amino acids are changed; (D) a peptide having: the reverse sequence of any of (A) to (C); an amino acid sequence which is the same as the reverse sequence of (A) except that one or several basic amino acids are changed; or an amino acid sequence which is the same as the reverse sequence of (A) except that 1 to 5 amino acids are changed.

Abstract: A microparticle includes an agglomerate of a hydrophilic active substance containing particle, which particle includes an amphiphilic polymer composed of a hydrophobic segment of poly(hydroxy acid) and a hydrophilic segment of polysaccharides or polyethylene glycol, and a hydrophilic active substance. It is characterized by an efficient inclusion of the hydrophilic active substance, and a release of the hydrophilic active substance at an appropriate speed in the human body, and is hence very useful as a DDS pharmaceutical preparation.

Abstract: A cell-penetrating peptide of (A) to (D) below gives cell membrane permeability and transmucosal absorbability to a physiologically active substance: (A) a peptide having the amino acid sequence of SEQ ID NO:1; (B) a peptide represented by SEQ ID NO:1 except that one or several basic amino acids are changed; (C) a peptide represented by SEQ ID NO:1 except that 1 to 5 amino acids are changed; (D) a peptide having: the reverse sequence of any of (A) to (C); an amino acid sequence which is the same as the reverse sequence of (A) except that one or several basic amino acids are changed; or an amino acid sequence which is the same as the reverse sequence of (A) except that 1 to 5 amino acids are changed.

Abstract: An immunogenic composition includes as an effective ingredient an antigen-adjuvant microparticle complex containing an antigen encapsulated in an adjuvant microparticle composed of an amphiphilic polymer(s) whose hydrophobic segment is a poly(hydroxy acid), or a particle composed of the antigen-adjuvant microparticle complex associated together, can induce a high immune response against the antigen even with a small amount of the antigen and a small number of doses, so that the immunogenic composition is useful as a vaccine effective for therapy and prophylaxis of infectious diseases, cancer and the like.

Abstract: By a pharmaceutical composition for nasal administration comprising a hydrophilic bioactive substance and any one of (a) to (c) below, with the proviso that a C-terminal amidated peptide is excluded, a hydrophilic bioactive substance having a low transmucosal absorption capability which has conventionally been able to be administered by only injection can be nasally administered. Such a pharmaceutical composition is useful for improvement of the pain and the inconvenience of patients caused by administration by injection. (a) A peptide having the amino acid sequence shown in SEQ ID NO:1. (b) A peptide having the same amino acid sequence as shown in SEQ ID NO:1 except that one or several amino acids are deleted, substituted and/or added, the peptide having nasal mucosal permeability. (c) A peptide having an amino acid sequence represented by the reverse sequence of (a) or (b), the peptide having nasal mucosal permeability.

Abstract: A microparticle includes an agglomerate of a hydrophilic active substance containing particle, which particle includes an amphiphilic polymer composed of a hydrophobic segment of poly (hydroxy acid) and a hydrophilic segment of polysaccharides or polyethylene glycol, and a hydrophilic active substance. It is characterized by an efficient inclusion of the hydrophilic active substance, and a release of the hydrophilic active substance at an appropriate speed in the human body, and is hence very useful as a DDS pharmaceutical preparation.

Abstract: A peptide consisting of an amino acid sequence represented by any one of SEQ ID Nos. 1 to 76 of the present invention, a peptide consisting of an amino acid sequence in which one or several amino acids are substituted, deleted, inserted or added in these amino acid sequences, and having an ability to bind to, or to be taken into an activated vascular endothelial cell, or a peptide containing the above peptide as a partial sequence, and having an ability to bind to, or to be taken into an activated vascular endothelial cell is a novel peptide ligand specifically binding to a neovascular endothelial cell, and such a ligand can be effectively used for treating and diagnosing a disease accompanying vascularization such as a solid tumor.

Abstract: An adsorbent of high-mobility-group proteins (HMG protein) which can remove HMG protein in body fluid is disclosed. The adsorbent according to the present invention has a water-insoluble carrier on which (a) substance(s) having (a) hydrogen-bondable functional group(s) and/or (a) hydrophobic functional group(s) is(are) immobilized.

Abstract: A fine particle comprising an amphiphilic polymer, further comprising an inner nucleus of hydrophilic segment of amphiphilic polymer, and a hydrophobic outer layer of hydrophobic segment of amphiphilic polymer, and having a surface modifier bonded to the hydrophobic outer layer. A fine particle of the invention effectively enclose protein, peptide drug, nucleic acid medicine of hydrophilic property and large molecular weight in the inner nucleus of hydrophilic segment of amphiphilic polymer, and are preferable for stabilizing in the body and promoting absorption.

Abstract: A pharmaceutical preparation has a ligand structure specifically recognizing a target site and an amphiphilic compound having a hydrophobic or amphiphilic group. The pharmaceutical preparation employs an amphiphilic compound of specific structure obtained by introducing a chained hydrophilic group with an appropriate flexibility, and thus becomes a fine particle suited for drug targeting. The pharmaceutical preparation is expected to give a prolonged pharmacological effect. A particulate preparation exhibiting a remarkable site targeting property can be formed. Further, according to the selection of matrix forming material, the drug releasing property can be controlled.

Abstract: A user circuit unit is configured by a gate array, a PLL circuit is configured in a microprocessor macro unit, a clock frequency output from the PLL circuit in the microprocessor macro unit is directly distributed to a user circuit unit (CLK 3), and the clock frequency distributed to the user circuit unit is distributed to the microprocessor macro unit through a frequency divider configured by the user circuit unit.

Abstract: An adsorbent of high-mobility-group proteins (HMG protein) which can remove HMG protein in body fluid is disclosed. The adsorbent according to the present invention has a water-insoluble carrier on which (a) substance(s) having (a) hydrogen-bondable functional group(s) and/or (a) hydrophobic functional group(s) is(are) immobilized.

Abstract: A user circuit unit is configured by a gate array, a PLT circuit is configured in a microprocessor macro unit, a clock frequency output from the PLL circuit in the microprocessor macro unit is directly distributed to auser circuit unit (CLK 3), and the clock frequency distributed to the user circuit unit is distributed to the microprocessor macro unit through a frequency divider configured by the user circuit unit.

Abstract: An adsorbent of high-mobility-group proteins (HMG protein) which can remove HMG protein in body fluid is disclosed. The adsorbent according to the present invention comprises a water-insoluble carrier on which (a) substance(s) having (a) hydrogen-bondable functional group(s) and/or (a) hydrophobic functional group(s) is(are) immobilized.

Abstract: A drug for prevention and therapy of diseases caused by fibrinoid formation or thrombus formation, as well as a model animal of fibrinoid formation or thrombus formation in the lung is disclosed. The drug for preventing and treating diseases caused by fibrinoid formation or thrombus formation in the lung according to the present invention comprises an inhibitor of interleukin 6 as an effective ingredient. The model animal of the diseases caused by fibrinoid formation or thrombus formation in the lung is a rat in which fibrinoid formation or thrombus formation actually occurs by induction with interleukin 6.

Abstract: A column comprising an insoluble carrier and an anti-.beta..sub.2 -microglobulin antibody immobilized to the carrier can specifically adsorb and remove .beta..sub.2 -microglobulin in the blood. This column is useful for the prevention and treatment of diseases such as carpal tunnel syndrome observed in patients undergoing blood dialysis.